Atara Biotherapeutics, Inc.

0.61 USD
-0.02 (-2.81%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Atara Biotherapeutics, Inc. stock is down -52.48% since 30 days ago. The next earnings date is Feb 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 9 November’s closed higher than October. In the last 2 Unusual Options Trades, there were 2 PUTs. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
10 Oct 17:34 17 Nov, 2023 2.50 PUT 199 715
01 Nov 14:21 17 Nov, 2023 2.50 PUT 800 1018

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

  • Goldman Sachs
    Fri Nov 10, 10:53
  • Evercore Partners
    Thu Nov 9, 09:37
  • HC Wainwright & Co.
    Thu Nov 9, 07:44
  • Mizuho
    Thu Nov 9, 07:11